Structural and antigenic variations in the spike protein of emerging SARS-CoV-2 variants
The Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) virus is continuously
evolving, and this poses a major threat to antibody therapies and currently authorized …
evolving, and this poses a major threat to antibody therapies and currently authorized …
Current status of therapeutic monoclonal antibodies against SARS-CoV-2
S Kumar, A Chandele, A Sharma - PLoS pathogens, 2021 - journals.plos.org
The ongoing Coronavirus Disease 2019 (COVID-19) pandemic has taken a toll on millions
of lives worldwide. Currently, India has the second highest number of active COVID-19 …
of lives worldwide. Currently, India has the second highest number of active COVID-19 …
[HTML][HTML] SARS-CoV-2 mRNA vaccination induces functionally diverse antibodies to NTD, RBD, and S2
In this study we profiled vaccine-induced polyclonal antibodies as well as plasmablast-
derived mAbs from individuals who received SARS-CoV-2 spike mRNA vaccine. Polyclonal …
derived mAbs from individuals who received SARS-CoV-2 spike mRNA vaccine. Polyclonal …
[HTML][HTML] The plasmablast response to SARS-CoV-2 mRNA vaccination is dominated by non-neutralizing antibodies and targets both the NTD and the RBD
In this study we profiled vaccine-induced polyclonal antibodies as well as plasmablast
derived mAbs from individuals who received SARS-CoV-2 spike mRNA vaccine. Polyclonal …
derived mAbs from individuals who received SARS-CoV-2 spike mRNA vaccine. Polyclonal …
Probing affinity, avidity, anticooperativity, and competition in antibody and receptor binding to the SARS-CoV-2 spike by single particle mass analyses
Determining how antibodies interact with the spike (S) protein of the SARS-CoV-2 virus is
critical for combating COVID-19. Structural studies typically employ simplified, truncated …
critical for combating COVID-19. Structural studies typically employ simplified, truncated …
A spike-targeting bispecific T cell engager strategy provides dual layer protection against SARS-CoV-2 infection in vivo
Neutralizing antibodies exert a potent inhibitory effect on viral entry; however, they are less
effective in therapeutic models than in prophylactic models, presumably because of their …
effective in therapeutic models than in prophylactic models, presumably because of their …
[HTML][HTML] Native, engineered and de novo designed ligands targeting the SARS-CoV-2 spike protein
CFS Costa, AJM Barbosa, AMGC Dias… - Biotechnology …, 2022 - Elsevier
The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is responsible for the
deadly coronavirus disease 2019 (Covid-19) and is a concerning hazard to public health …
deadly coronavirus disease 2019 (Covid-19) and is a concerning hazard to public health …
High-resolution analysis of long-term serum antibodies in humans following convalescence of SARS-CoV-2 infection
A Facciuolo, E Scruten, S Lipsit, A Lang… - Scientific Reports, 2022 - nature.com
Long-term antibody responses to SARS-CoV-2 have focused on responses to full-length
spike protein, specific domains within spike, or nucleoprotein. In this study, we used high …
spike protein, specific domains within spike, or nucleoprotein. In this study, we used high …
Development of COVID-19 therapies: Nonclinical testing considerations
P Baldrick - Regulatory Toxicology and Pharmacology, 2022 - Elsevier
Therapies have been developed in the last couple of years to allow vaccination against, or
treatment of patients with, COVID-19 using pathways such as Emergency Use Authorization …
treatment of patients with, COVID-19 using pathways such as Emergency Use Authorization …
The First Chemically-Synthesised, Highly Immunogenic Anti-SARS-CoV-2 Peptides in DNA Genotyped Aotus Monkeys for Human Use
ME Patarroyo, MA Patarroyo, MP Alba… - Frontiers in …, 2021 - frontiersin.org
Thirty-five peptides selected from functionally-relevant SARS-CoV-2 spike (S), membrane
(M), and envelope (E) proteins were suitably modified for immunising MHC class II (MHCII) …
(M), and envelope (E) proteins were suitably modified for immunising MHC class II (MHCII) …